JP2022521797A5 - - Google Patents

Info

Publication number
JP2022521797A5
JP2022521797A5 JP2021550133A JP2021550133A JP2022521797A5 JP 2022521797 A5 JP2022521797 A5 JP 2022521797A5 JP 2021550133 A JP2021550133 A JP 2021550133A JP 2021550133 A JP2021550133 A JP 2021550133A JP 2022521797 A5 JP2022521797 A5 JP 2022521797A5
Authority
JP
Japan
Application number
JP2021550133A
Other languages
Japanese (ja)
Other versions
JPWO2020176654A5 (https=
JP7709379B2 (ja
JP2022521797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019944 external-priority patent/WO2020176654A1/en
Publication of JP2022521797A publication Critical patent/JP2022521797A/ja
Publication of JPWO2020176654A5 publication Critical patent/JPWO2020176654A5/ja
Publication of JP2022521797A5 publication Critical patent/JP2022521797A5/ja
Application granted granted Critical
Publication of JP7709379B2 publication Critical patent/JP7709379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021550133A 2019-02-27 2020-02-26 イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼpの機能の使用 Active JP7709379B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962811432P 2019-02-27 2019-02-27
US62/811,432 2019-02-27
US201962819204P 2019-03-15 2019-03-15
US62/819,204 2019-03-15
US201962825667P 2019-03-28 2019-03-28
US62/825,667 2019-03-28
US201962840254P 2019-04-29 2019-04-29
US62/840,254 2019-04-29
US201962871694P 2019-07-08 2019-07-08
US62/871,694 2019-07-08
US201962885055P 2019-08-09 2019-08-09
US62/885,055 2019-08-09
US201962901142P 2019-09-16 2019-09-16
US62/901,142 2019-09-16
US201962931043P 2019-11-05 2019-11-05
US62/931,043 2019-11-05
US202062975088P 2020-02-11 2020-02-11
US62/975,088 2020-02-11
PCT/US2020/019944 WO2020176654A1 (en) 2019-02-27 2020-02-26 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Publications (4)

Publication Number Publication Date
JP2022521797A JP2022521797A (ja) 2022-04-12
JPWO2020176654A5 JPWO2020176654A5 (https=) 2023-02-17
JP2022521797A5 true JP2022521797A5 (https=) 2023-02-17
JP7709379B2 JP7709379B2 (ja) 2025-07-16

Family

ID=72238693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550133A Active JP7709379B2 (ja) 2019-02-27 2020-02-26 イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼpの機能の使用

Country Status (7)

Country Link
US (1) US12459945B2 (https=)
EP (1) EP3930714A4 (https=)
JP (1) JP7709379B2 (https=)
CN (2) CN113795251B (https=)
AU (2) AU2020228047B2 (https=)
CA (1) CA3131740A1 (https=)
WO (1) WO2020176654A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
EP4488279A1 (en) * 2023-07-03 2025-01-08 Centro Atlantico del Medicamento S.A (Ceamed, S.A) Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp)
WO2025011546A1 (en) * 2023-07-10 2025-01-16 Acelon Therapeutics Human caseinolytic protease p agonists and uses thereof
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
DE59408453D1 (de) 1993-04-23 1999-08-12 Hoechst Ag Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス,インコーポレイティド 核酸分析法
WO2008130584A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
US20110275647A1 (en) * 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
WO2012079164A1 (en) 2010-12-16 2012-06-21 The Governing Council Of The University Of Toronto Activators of cylindrical proteases
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
AU2017310529B2 (en) 2016-08-12 2021-08-19 Edwin J. Iwanowicz Protein kinase regulators
WO2018031987A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US20220143024A1 (en) 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Similar Documents

Publication Publication Date Title
JP2022520997A5 (https=)
CN306128045S (https=)
CN306002282S (https=)
CN305557530S (https=)
CN305561119S (https=)
CN305562429S (https=)
CN305604048S (https=)
CN305610646S (https=)
CN305641958S (https=)
CN305655057S (https=)
CN305655432S (https=)
CN305656539S (https=)
CN306133145S (https=)
CN305674697S (https=)
CN305691486S (https=)
CN305696699S (https=)
CN305700446S (https=)
CN305701458S (https=)
CN305721422S (https=)
CN305774963S (https=)
CN305782144S (https=)
CN305800658S (https=)
CN305920695S (https=)
CN305922219S (https=)
CN305923677S (https=)